pharmaceutical daily

December 9, 2015 Off

Bayer’s Xarelto in deep vein thrombosis treatment confirm low rates of major bleeding seen in pivotal trial

The non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study in patients with cancer-associated thrombosis (CAT) – both showing low rates of major bleeding and recurrent venous thromboembolism (VTE) with Xarelto (rivaroxaban). Results from the two studies were presented at the 2015 ASH Annual Meeting, and XALIA findings were also simultaneously published in the Lancet Haematology.

December 9, 2015 Off

FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients

By Dino Mustafić

The U.S. Food and Drug Administration has approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

December 9, 2015 Off

FDA nods for Vonvendi for von Willebrand disease

By Dino Mustafić

The U.S. Food and Drug Administration on Tuesday approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of…

December 9, 2015 Off

Bristol-Myers wraps up Cardioxyl buy. Dividend increase

By Dino Mustafić

Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.

December 9, 2015 Off

Novartis delivers 300M pediatric antimalarial no-profit-treatments since 2009

By Dino Mustafić

Novartis has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.

December 7, 2015 Off

Open-source software that helps track embryonic development and movement of neuronal cells throughout the body of the worm available to scientists

By Dino Mustafić

A new, open-source software that can help track the embryonic development and movement of neuronal cells throughout the body of the worm, is now available to scientists.

December 7, 2015 Off

Johnson Johnson buys Novira Therapeutics

By Dino Mustafić

Johnson & Johnson has completed the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

December 4, 2015 Off

TLipo Escultura and JAT Natural Corp recalling all Lipo Escultura

By Dino Mustafić

The FDA has informed that TLipo Escultura Corp. of Brooklyn, NY dba JAT Productos Naturales Corp., and JAT Natural Products…

December 4, 2015 Off

Lilly quits developing basal insulin peglispro

By Dino Mustafić

Eli Lilly and Company will cease development of basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes, in order to focus research and development efforts on other assets in its portfolio and pipeline.

December 4, 2015 Off

Genomic Vision partners up with the University-Hospital Institute (IHU) Imagine

By Dino Mustafić

Genomic Vision – has signed a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster.